RNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating Biomarkers

Home
|
Posters
|

Training Courses

|
Media
|
Testimonials
|

Keynote Speakers

Xandra Breakefield Professor, Mass General Hospital (MGH)/Harvard Medical School	Clark Chen Co-Director, University of California-San Diego	Shana Kelley Professor, University of Toronto	Joshua Levin Senior Group Leader, Research Scientist, Stanley Center for Psychiatric Research, Klarman Cell Observatory, The Broad Institute of MIT and Harvard	Chwee Teck Lim NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute, National University of Singapore	John Palma Chief Medical Officer, Roche Sequencing Solutions
Steve Soper Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas	Phil Stephens Chief Scientific Officer, Foundation Medicine

Overview

The Third Annual SELECTBIO Circulating Biomarkers World Congress 2016 brings together academic researchers as well as industry participants to present and discuss the most up-to-date research and commercial activities in the translation of various circulating biomarker classes towards the clinic.

The RNA-Seq and Digital PCR for Liquid Biopsies Conference Track brings together presenters from around the world to offer a comprehensive picture from research, commercial, and regulatory perspectives as to the deployment of biomarkers for precision medicine, and technical as well as economic and regulatory considerations in the development of liquid biopsies for the different cancer sub-classes as well as other disease areas.

A co-located exhibit hall features companies developing technologies and products for the complete workflow from sample isolation, preparation, through data analysis.

Conference delegates receive access to all three co-located conference tracks, can mix-and-match presentations from all three tracks thereby maximizing the conference experience, and can network with delegates from the various co-located tracks and exhibition.

Agenda Topics

Circulating Biomarkers vs. Tissue-based Biomarkers for Companion Diagnostics Development
Companion Diagnostics in Various Disease Classes

Autoimmune Disease
Cancer
Cardiovascular Disease
CNS and Neurodegenerative Diseases

Converting LDTs into FDA-Approved Tests
Epigenetic Modifications (Hypermethylation of specific Genes) as Biomarkers for Diagnostics Development
Next-Generation Sequencing (NGS) in Companion Diagnostics
Potential of microRNAs as Biomarkers for Diagnostics Development
Protein Biomarkers versus Nucleic Acid Biomarkers for Companion Diagnostics Development
US vs. EU vs. Asia/Pacific Regulatory Landscape for Companion Diagnostics

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Distinguished Faculty

David Ting, Assistant Professor Of Medicine, Harvard Medical School
Yaoyu Wang, Associate Director, Dana-Farber Cancer Institute
Bakhos A. Tannous, Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School
Mark Connelly, Chief Industrial Operations and R&D Officer, U.S., Menarini Silicon Biosystems, Inc.
Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D
Laura Housman, Global Head, Pharmaceutical Business; Senior Vice President, Corporate Development, Molecular Health
Dima Ter-Ovanesyan, PhD Student/George Church and Aviv Regev Laboratories, Harvard University
Mike Makrigiorgos, Professor, Dana-Farber Cancer Institute/Harvard Medical School
Dana Gabuzda, Professor of Neurology, Dana-Farber Cancer Institute and Harvard Medical School
Robert Kitchen, Research Associate, Yale University
Jorge Goldstein, Senior Director, Sterne Kessler Goldstein and Fox PLLC
John F. Beeler, Vice President, Business Development, Inivata Ltd.

Corporate Sponsors	Web Sponsors	Offical Journal Partner	Networking